Navigation Links
Novel discovery by Einstein scientists could lead to much-needed kidney failure treatment
Date:3/12/2008

March 12, 2008 (BRONX, NY) The unwanted activation of an important cell-signaling pathway may play a role in two kidney problems that are major causes of end-stage renal disease, scientists at the Albert Einstein College of Medicine of Yeshiva University have found. Their research, which opens up a novel approach for treating kidney failure, is described in the March issue of Nature Medicine. The study was led by Dr. Katalin Susztak, an assistant professor of medicine (nephrology) at Einstein.

The kidneys filter waste products from the blood and maintain the bodys fluid balance by producing urine. The filtration is carried out by numerous capillary tufts within the kidney known as glomeruli. Kidney disease occurs when glomeruli become damaged and can no longer perform their filtering function. Kidney damage may ultimately progress to end-stage renal disease, in which patients need dialysis or a kidney transplant.

The Einstein scientists focused on cells known as podocytes that line the glomeruli. Since dysfunction of podocytes cells is important in progressive kidney disease, and since a cell-signaling pathway called Notch is crucial in podocyte development, the Einstein researchers reasoned that aberrant Notch signaling might play a role in causing kidney disease.

The Notch signaling pathway plays a key role in embryonic development of humans and most other multicellular organisms. The Notch pathway tells some cells to proliferate and others to undergo programmed cell death as it profoundly affects the way tissues are organized. Faulty Notch signaling has been found in several types of cancer and in many other diseases such as multiple sclerosis.

Collectively, the observations made in the Einstein study offer strong evidence that aberrant Notch signaling is also involved in diabetic nephropathy (DNP) and focal segmental glomerulosclerosis (FSGS)two of the major causes of end-stage renal disease. For example:

  • When comparing biopsy samples from healthy kidneys and kidneys from people with DNP and FSGS, the researchers found evidence that the Notch pathway was active in diseased but not in healthy kidneys.

  • The researchers bred a strain of mice in which they could specifically activate the Notch pathway within podocytes. Examination revealed that the podocytes in these mice underwent programmed cell death, and the mice themselves died from end-stage renal failure.

  • After inducing glomerular disease in mice by injecting them with a toxic chemical, the researchers were able to protect the rats from developing kidney disease by injecting them with a gamma secretase inhibitorone of a class of compounds known to shut off the Notch pathway.

An exciting aspect of this new work is the therapeutic implications, according to a Nature Medicine commentary on the Einstein study written by kidney experts from the University of Michigan Medical Center. The experts noted that gamma secretase inhibitors, like the one that protected the mice from kidney disease in this study, are already in phase 1 and 2 clinical trials for treating diseases including Alzheimers and leukemia. The Einstein findings, they wrote, provide some hope that researchers in the field of kidney disease can reverse the grim record of the last 20 years during which no new therapeutic agent has been successfully implemented for treating end-stage kidney disease.


'/>"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. Scripps Florida awarded $7.6 million grant to develop novel treatment for Parkinsons disease
2. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
3. USC researchers discover novel way to develop tumor vaccines
4. Novel mechanism found that may boost impaired function of leukemia protein
5. Novel method to reveal drug targets
6. Novel link between excessive nutrient levels and insulin resistance
7. Novel organic metal hybrids that will revolutionize materials science and chemical engineering
8. Novel mathematical model predicts new wave of drug-resistant HIV infections in San Francisco
9. Novel approach strips staph of virulence
10. UCSD research team identifies novel anticancer drug from the sea
11. Novel compound may lessen heart attack damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 04, 2016 , ... The RIDER Institute announces an IndieGoGo ... broad-spectrum antiviral therapeutics. DRACOs have proven effective against all 18 viruses tested in ... http://igg.me/at/EndTheVirus and runs for 60 days, we are raising new funding ...
(Date:5/4/2016)... ... May 04, 2016 , ... a2z, Inc. ... Society™ and Canadian Association for Enterostomal Therapy (CAET) will be utilizing powerful and ... tools to attendees and exhibitors for the 2016 WOCN Society & CAET Joint ...
(Date:5/4/2016)... ... , ... May kicked off with Melanoma Monday , a multi-agency effort ... Turner is encouraging her patients, as well as residents all around Dallas, Cleburne, Irving, ... now and in the future. , The dermatology-specific awareness month ends with “Don’t Fry ...
(Date:5/4/2016)... ... 04, 2016 , ... Recognizing that lifestyle medicine is essential to health and ... tapped David Katz, MD, MPH, president of the American College of Lifestyle Medicine, as ... is especially gratifying,” said Katz. “There is so much opportunity to add years to ...
(Date:5/4/2016)... TX (PRWEB) , ... May 04, 2016 , ... ... Nightstick all-LED multi-function small and compact tactical (6.7 inch) dual-light flashlights in models ... Las Vegas, model NSP-9842XL (average retail starting at $59.95) uses 2 included CR-123 ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 BiondVax Pharmaceuticals ... Dr. Ron Babecoff , will be attending the Joseph ... . On Thursday, May 5, Dr. Babecoff ... presented by Joseph Gunner & Co, taking place ... presentation that Dr. Babecoff will be using is downloadable from ...
(Date:5/4/2016)... May 4, 2016 Valeritas Holdings, ... an alternative public offering (APO). This was accomplished via ... Valeritas, Inc. and a private placement of approximately 5 ... per share. Under the terms of the ... Valeritas Holdings, Inc. will trade on the OTC Markets ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Actinic Keratosis Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Actinic Keratosis market valuations and forecast, ...
Breaking Medicine Technology: